Investors are weighing the merits of abbott and dexcom as options in the continuous glucose monitoring (cgm) market. Some outlets suggest abbott may have an advantage, citing its dual-analyte approach and ongoing growth in the cgm sector, while others highlight dexcom's position and potential. The relative strengths and weaknesses of the two companies are being debated, with some outlets identifying potential flaws in dexcom's approach.